Navigation Links
Drug Boosts Natural Growth Hormone in Seniors

MK-677 brought muscle mass, but long-term effects on vitality unclear, scientists say

THURSDAY, Nov. 6 (HealthDay News) -- An experimental drug can restore the amounts of muscle-linked growth hormone in seniors to youthful levels, a new study shows.

Those on the therapy also gained muscle mass over the two-year trial, scientists say. However, there's no clear indication that this led to significant improvements in their strength or function.

Still, it does raise the hope that by increasing natural growth hormone Americans might be able to beat back the ravages of age.

"As we all get older, our body composition changes," explained study author Dr. Michael O. Thorner, a teaching professor of internal medicine at the University of Virginia in Charlottesville. "So, people in their 80s and 90s all look the same: their fat is distributed in the center and the abdomen, and they lose a lot of muscle mass."

"This has become an increasing problem as life expectancy has increased from 45 at the turn of the century to now over 80," he continued. "Obviously people would like to remain independent and functional as long as possible, but these changes work against them."

The challenge is to stop or at least slow down those changes.

"Because this age-related reduction in muscle mass is associated with a decrease in growth hormone secretion, the rationale for the therapy we're studying is to try and address the problem by boosting the normal secretion of this hormone," Thorner said.

His team reported its findings in the Nov. 3 issue of the Annals of Internal Medicine.

Human growth hormone, produced naturally by the body's pituitary gland, is essential to healthy development and the maintenance of tissues and organs. But as people enter their 30s and 40s, levels of the hormone start to decline. The use of synthetic versions of human growth hormone has also become the focus of "sports doping" headlines, with well-known athletes allegedly turning to the drug for its reputed performance-enhancing properties.

Aging Americans are also showing an interest in synthetic human growth hormone as a hoped-for "elixir of youth." According to the American College of Physicians, it's estimated that some patients spend as much as $1,000 to $2,000 per month on the drug for anti-aging purposes.

But what if there were a way to jumpstart the aging body's natural supply of growth hormone?

In the current work, the authors had 65 healthy adults between the ages of 60 and 81 receive either a placebo or a so-called "oral ghrelin mimetic" called MK-677, over the course of one year. MK-677 is an experimental medication that prompts the body to release naturally produced growth hormone. The drug was ingested once daily in pill form.

After the end of the year, those who had been taking a placebo were switched to MK-677. At the same time, the group who had already been taking the drug either continued to take the medication or were taken off it.

Thorner's team found that patients who had received the therapy experienced an increase in growth hormone levels equivalent to levels seen among healthy young adults. Their lean, fat-free muscle mass also increased, as did overall body weight and the amount of fat distributed to the arms and legs.

"Whereas those who didn't get the growth-hormone boosting therapy lost about one pound of muscle in a year, those who got [the drug] gained about two pounds of muscle mass and experienced appetite stimulation," Thorner added. "Although fat increase was the same between the two groups, there was a difference in [fat] distribution, so that among those treated with the drug 50 percent of it was distributed to the limbs, rather than all to the center, as usual."

Patients who had been on MK-677 and then were taken off the medication saw all of the drug's beneficial effects dissipate, the authors reported. In contrast, those who stayed on the regimen maintained their gains throughout the total two-year period.

Insulin sensitivity decreased among those taking MK-677, while their blood sugar increased. The therapy did not have any observable effect on the muscularity of the thigh area -- a key source of mobility strength -- nor did it have any impact on overall muscle strength or activity function, the team noted.

"But the patients we studied were healthy to begin with," Thorner stressed. "So, we believe that we now need a longer-term study with possibly more frail individuals, to see if we can demonstrate any possible change or improvement in function as a result of the therapy."

Thorner noted that a person's growth hormone levels are highest during mid-puberty, but have dropped by about half by the time men and women turn 30. The decline continues with age, with levels diminishing at a rate of about 50 percent every 7 years.

Dr. Todd Schlifstein, an assistant professor of rehabilitation medicine at the New York University School of Medicine in New York City, called the study "very interesting" but agreed that more research is needed.

"I think it certainly enlightens an area where there certainly seems like there is a potential for a benefit for elderly patients," he said. "But now it needs to be looked at further in a functionality type of way, to see how an increase in appetite, body energy, and lean muscle mass actually translates into how a patient actually walks, for example, and how it impacts on their over well-being, which is much harder to test. But that's the next step."

More information

There's more on maintaining muscle mass as you age at the U.S. National Institute on Aging.

SOURCES: Michael O. Thorner, MB, BS, Dsc, teaching professor, internal medicine, University of Virginia, Charlottesville, Va.; Todd Schlifstein, M.D., assistant professor, rehabilitation medicine, New York University School of Medicine, New York City; Nov. 3, 2008, Annals of Internal Medicine

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New treatment boosts muscle function in myasthenia gravis
2. Heavy Drinking Boosts Stroke Risk for Chinese Men
3. Traffic Fumes Plus Genes Boosts Kids Asthma Risk
4. Heart Attack Boosts Diabetes Risk
5. Smoking Boosts Risk for Head, Neck Cancers
6. Continued Statin Use Boosts Post-Stroke Outcomes
7. Counseling Boosts Alzheimers Caregivers Health
8. Bypass Off-Pump Boosts Womens Outcomes
9. Diabetes Drug Avandia Boosts Heart Risks: Study
10. $1 Million Gift Boosts Downriver Community
11. Doctors Office Outreach Boosts Colon Cancer Screening
Post Your Comments:
Related Image:
Drug Boosts Natural Growth Hormone in Seniors
(Date:11/25/2015)... ... November 25, 2015 , ... ... direct sauna parts and accessories. , Sauna accessories help improve the bather experience ... and personality. From basic styles for the purist looking for simplicity in design ...
(Date:11/25/2015)... ... 2015 , ... For the first time, Vitalalert is donating half of its ... The partnership between the two groups began in 2014 with Vitalalert pledging a portion ... International was founded in 1954 and is an international Christian-based health organization whose mission ...
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 25, ... center for the Narconon network, announced the release of a new cutting edge recovery ... Narconon organization has been working with drug- and alcohol-addicted individuals with the purpose to ...
(Date:11/25/2015)... ... 2015 , ... Smiles by Stevens is pleased to announce the ... While many patients are aware of the benefits of Botox® in the treatment of ... suffering with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... In an ... Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of ... and surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
(Date:11/25/2015)... MINNEAPOLIS , Nov. 25, 2015  ARKRAY ... care products, continues to provide evidence demonstrating the accuracy ... the World Congress on Insulin Resistance, Diabetes and Cardiovascular ... showed that both the Company,s GLUCOCARD ® 01 ... met high accuracy requirements. The ability to accurately measure ...
Breaking Medicine Technology: